Anti-CD38 Pretargeted Radioimmunotherapy Eradicates Multiple Myeloma Xenografts In a Murine Model

被引：3
|
作者：
Green, Damian J.
Jones, Jon C.
Hylarides, Mark D.
Hamlin, Donald K.
Wilbur, D. Scott
Lin, Yukang
Kenoyer, Aimee L.
Frayo, Shani L.
Bensinger, William I.
Gopal, Ajay K.
Orozco, Johnnie J.
Gooley, Theodore A.
Wood, Brent L.
Pagel, John M.
Press, Oliver W.
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.882.882
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
882
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Implications for the monitoring of patients with multiple myeloma undergoing treatment with the anti-CD38 monoclonal daratumumab
    Thirkettle, Sally
    Russell, Joanne
    Wilson, Sarah
    Ganijee, Tasneem
    Kulkarni, Samar
    Cavet, Jim
    Monaghan, Phillip J.
    ANNALS OF CLINICAL BIOCHEMISTRY, 2020, 57 (02) : 178 - 181
  • [32] Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy
    Zamagni, Elena
    Tacchetti, Paola
    Pantani, Lucia
    Cavo, Michele
    EXPERT REVIEW OF HEMATOLOGY, 2018, 11 (05) : 423 - 435
  • [33] Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapy
    Pagel, John M.
    Hedin, Nathan
    Drouet, Lacey
    Wood, Brent L.
    Pantelias, Anastasia
    Lin, Yukang
    Hamlin, Donald K.
    Wilbur, D. Scott
    Gopal, Ajay K.
    Green, Damian
    Appelbaum, Frederick R.
    Pressl, Oliver W.
    BLOOD, 2008, 111 (04) : 2261 - 2268
  • [34] Innovative Anti-CD38 and Anti-BCMA Targeted Therapies in Multiple Myeloma: Mechanisms of Action and Resistance
    De Novellis, Danilo
    Fontana, Raffaele
    Giudice, Valentina
    Serio, Bianca
    Selleri, Carmine
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (01)
  • [35] SAR650984, an anti-CD38 antibody, shows anti-tumor activity in a preclinical model of multiple myeloma.
    Hann, Byron
    Cai, T. I.
    Wang, Donghui
    Hom, Yun-Kit
    Aftab, Blake T.
    Martin, Tom
    Wolf, Jeffrey
    CANCER RESEARCH, 2013, 73 (08)
  • [36] Monoclonal anti-CD38 therapy in human myeloma: retrospects and prospects
    Horenstein, Alberto L.
    Faini, Angelo C.
    Morandi, Fabio
    Ortolan, Erika
    Storti, Paola
    Giuliani, Nicola
    Richardson, Paul G.
    Malavasi, Fabio
    FRONTIERS IN IMMUNOLOGY, 2025, 16
  • [37] A combination of humanized anti-BCMA and murine anti-CD38 CAR-T cell therapy in patients with relapsed or refractory multiple myeloma
    Zhang, Huan
    Liu, Man
    Xiao, Xia
    Lv, Hairong
    Jiang, Yanyu
    Li, Xin
    Yuan, Ting
    Zhao, Mingfeng
    LEUKEMIA & LYMPHOMA, 2022, 63 (06) : 1418 - 1427
  • [38] Effects of Soluble and MicrovesicleBound Therapeutic Anti-CD38 Antibodies on Immune Effector Cells in Multiple Myeloma
    Faini, Angelo Corso
    Castella, Barbara
    Horenstein, Alberto
    Morandi, Fabio
    Malavasi, Fabio
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S418 - S418
  • [39] ANALYSIS OF THE USE OF THE ANTI-CD38 MONOCLONAL ANTIBODY IN PATIENTS WITH MULTIPLE MYELOMA FROM OUR CENTER
    Pimentel, Villar M. A.
    Anguita, Arance M. M.
    Almagro, Torres F.
    Lopez, Lopez J. A.
    HAEMATOLOGICA, 2021, 106 (10) : 337 - 337
  • [40] Clinical outcomes of retreatment with daratumumab-based regimens in anti-CD38 refractory multiple myeloma
    Tan, Carlyn Rose Co
    Rueda, Colin
    Shekarkhand, Tala
    Derkach, Andriy
    Korde, Neha
    Maclachlan, Kylee
    Hultcrantz, Malin
    Hassoun, Hani
    Mailankody, Sham
    Shah, Urvi A.
    Rajeeve, Sridevi
    Lahoud, Oscar Boutros
    Shah, Gunjan L.
    Scordo, Michael
    Chung, David J.
    Landau, Heather Jolie
    Giralt, Sergio
    Usmani, Saad Zafar
    Lesokhin, Alexander M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345